- Home
- ABEO vs PUBM Comparison
ABEO vs PUBM Comparison
Compare ABEO & PUBM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABEO | PUBM |
|---|---|---|
| Founded | 1974 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 307.5M | 303.6M |
| IPO Year | 2005 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ABEO | PUBM |
|---|---|---|
| Price | $5.49 | $9.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $20.00 | $12.43 |
| AVG Volume (30 Days) | ★ 1.0M | 685.9K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 165.16 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,998,000.00 | ★ $282,926,000.00 |
| Revenue This Year | $1,024.31 | $3.44 |
| Revenue Next Year | $145.42 | $7.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 258.18 | N/A |
| 52 Week Low | $4.00 | $6.15 |
| 52 Week High | $7.54 | $13.26 |
Technical Indicators
Market Signals| Indicator | ABEO | PUBM |
|---|---|---|
| Relative Strength Index (RSI) | 51.22 | 51.72 |
| Support Level | $5.24 | $8.67 |
| Resistance Level | $5.54 | $9.95 |
| Average True Range (ATR) | 0.27 | 0.46 |
| MACD | -0.04 | -0.12 |
| Stochastic Oscillator | 35.50 | 19.74 |
Price Performance
Historical ComparisonAbout ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
About PUBM PubMatic Inc.
PubMatic Inc is a supply-side platform provider in the digital advertising technology market. These platforms help publishers, which supply digital ad inventory, manage their inventory, selling a high percentage of their inventory (increase the ad fill rate) and maximizing revenue per ad sold (optimize yield). The company generates revenue mainly by taking a piece of the ad sales that it enables. Buyers on the platform include intermediary buyers, such as demand-side platforms, or advertisers and ad agencies directly. Geographically, the company generates the majority of its revenue from the United States, followed by EMEA and APAC.